Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and OlderGlobeNewsWire • 02/28/25
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya VaccineGlobeNewsWire • 02/25/25
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and OlderGlobeNewsWire • 02/14/25
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025GlobeNewsWire • 02/03/25
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and OlderGlobeNewsWire • 01/31/25
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of IndiaGlobeNewsWire • 12/16/24
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian NordicGlobeNewsWire • 12/13/24
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/30/24
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox VaccineGlobeNewsWire • 10/29/24
Bavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/03/24